Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1981 2
1982 3
1983 3
1984 4
1985 6
1986 1
1987 12
1988 13
1989 15
1990 22
1991 22
1992 31
1993 49
1994 51
1995 77
1996 102
1997 92
1998 115
1999 105
2000 85
2001 107
2002 132
2003 127
2004 186
2005 198
2006 199
2007 261
2008 315
2009 398
2010 465
2011 583
2012 655
2013 689
2014 784
2015 835
2016 843
2017 829
2018 760
2019 746
2020 691
2021 737
2022 865
2023 798
2024 389

Text availability

Article attribute

Article type

Publication date

Search Results

11,720 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Lau J, et al. J Med Chem. 2015 Sep 24;58(18):7370-80. doi: 10.1021/acs.jmedchem.5b00726. Epub 2015 Sep 11. J Med Chem. 2015. PMID: 26308095
Metabolic Messengers: glucagon-like peptide 1.
Gribble FM, Reimann F. Gribble FM, et al. Nat Metab. 2021 Feb;3(2):142-148. doi: 10.1038/s42255-020-00327-x. Epub 2021 Jan 11. Nat Metab. 2021. PMID: 33432200 Review.
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, Roth J. Mehdi SF, et al. Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. eCollection 2023. Front Immunol. 2023. PMID: 37266425 Free PMC article. Review.
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, Forbes JM, Crawford S, Ramm G, Harcourt BE, Jandeleit-Dahm K, Advani A, Murphy AJ, Timmermann DB, Karihaloo A, Knudsen LB, El-Osta A, Drucker DJ, Cooper ME, Coughlan MT. Sourris KC, et al. Kidney Int. 2024 Jan;105(1):132-149. doi: 10.1016/j.kint.2023.09.029. Epub 2023 Dec 8. Kidney Int. 2024. PMID: 38069998 Free article.
Glucagon-like peptide-1 gene therapy.
Rowzee AM, Cawley NX, Chiorini JA, Di Pasquale G. Rowzee AM, et al. Exp Diabetes Res. 2011;2011:601047. doi: 10.1155/2011/601047. Epub 2011 Jun 20. Exp Diabetes Res. 2011. PMID: 21747830 Free PMC article. Review.
GLP-1a: Going beyond Traditional Use.
Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. Laurindo LF, et al. Int J Mol Sci. 2022 Jan 10;23(2):739. doi: 10.3390/ijms23020739. Int J Mol Sci. 2022. PMID: 35054924 Free PMC article. Review.
11,720 results
You have reached the last available page of results. Please see the User Guide for more information.